Table 1.
Baseline clinical characteristics of the study subjects.
| Characteristic | Teriparatide (N=27) | Denosumab (N=27) | Combination (N=23) | P value |
|---|---|---|---|---|
| Age (year) | 66.1 ± 7.9 | 65.1 ± 6.2 | 65.3 ± 8.0 | 0.88 |
| Body mass index (kg/m2) | 25.5 ± 3.7 | 23.8 ± 4.1 | 25.9 ± 5.2 | 0.20 |
| Percent White, non-Hispanic(no, %) | 27 (100%) | 24 (89%) | 20 (87%) | 0.17 |
| Clinical fracture at age >45 (no, %) | 14 (52%) | 10 (37%) | 8 (35%) | 0.40 |
| Previous oral bisphosphonate use (no, %) | 12 (44%) | 9 (33%) | 9 (39%) | 0.70 |
| Duration of use (months) | 45 ± 23 | 45 ± 26 | 25 ± 21 | 0.15 |
| Time since discontinuation (months) | 27 ± 20 | 35 ± 24 | 41 ± 18 | 0.31 |
| Serum 25-hydroxyvitamin D level (ng/mL) | 32.2 ±8.5 | 35.9 ± 11.0 | 34.8 ± 12.8 | 0.44 |
| Osteocalcin (ng/mL) | 46.3 ± 26.1 | 43.9 ± 20.2 | 55.0 ± 32.6 | 0.31 |
| CTX (ng/mL) | 0.34 ± 0.15 | 0.41 ± 0.22 | 0.44 ± 0.17 | 0.20 |
| DXA BMD (g/cm2) | ||||
| Posterior-anterior spine | 0.815 ± 0.109 | 0.863 ± 0.096 | 0.847 ± 0.130 | 0.31 |
| Femoral neck | 0.642 ± 0.064 | 0.639 ± 0.090 | 0.638 ± 0.054 | 0.98 |
| Total hip | 0.756 ± 0.072 | 0.759 ± 0.102 | 0.750 ± 0.068 | 0.93 |
| One third radius | 0.618 ± 0.072 | 0.608 ± 0.088 | 0.614 ± 0.072 | 0.92 |
Values are mean ±SD unless otherwise noted.